Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Benazepril; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Male or female patients, age 18 or older

• Given informed consent

• Diagnosed as having mild to moderate essential hypertension

Exclusion Criteria:

• Severe hypertension

• Significant preexisting cardiovascular and cerebrovascular disease

• Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II

• Advanced renal impairment

Other protocol-defined inclusion/exclusion criteria may apply.